After receiving amazing results in a large patient trial, Pfizer and BioNTech has partnered together to supply the Coronavirus vaccine, Europe and the USA are first in line to get the Experimental Coronavirus Vaccine.
The vaccine supply for the European Union would be produced by BioNTech’s manufacturing site in Germany and Pfizer’s manufacturing site in Belgium.
The USA has signed agreement with these companies to purchase 100 million doses and double that with European Union, with options for more.
The health minister of Germany Jens Spahn said Europeans will be getting their vaccine starting early next year, adding that his calculation factors in case of any potential setbacks.
The CEO and Co-founder of BioNtech Ugur Sahin said
“As a company founded in the heart of Europe, we are pleased to have concluded exploratory discussions with the European Commission, which would be our largest initial order to date.”
“Our aim is to develop a safe and effective vaccine to contribute to bringing this pandemic to an end in Europe and across the world. Today’s decision is a further illustration of how collaboration and solidarity can help address a global health crisis as an international community.”
The companies expect to ramp up production significantly next year with capacity for as many as 1.3 billion doses.
The Vaccine requires extreme freezing for long-term storage although it can stay at refrigerator temperatures for at least five days.
Shanghai Fosun pharmaceutical group co, is working with BioNTech on bringing the vaccine to china.
The CEO and chairman of Pfizer Albert Bourla said
“Pfizer and BioNTech’s anticipated agreement with the European Commission is an important step forward in our shared goal to have millions of doses of a vaccine against COVID-19 available for vulnerable populations before the end of the year.”
“We would like to thank the European Commission for its commitment and confidence in our development efforts.”
